NSE: VIVIMEDLAB | BSE: 532660

Download real time

6.55 0.04 (0.61%)

77.72% Fall from 52W High

120.2K NSE+BSE Volume

NSE 21 May, 2026 3:31 PM (IST)

54.3

Market Cap

Low in industry

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Vivimed Labs is on 28 May 2026 for the purpose of Audited Results See details

Vivimed Labs Ltd. share price target and research reports

Name: Latest research reports of Vivimed Labs Ltd. authored by Karvy and published by - Trendlyne research reports.
Item: Vivimed Labs Ltd.
Rating: 5
Author: Karvy

Latest analyst research reports with target prices and PDF download for VIVIMEDLAB, BSE:532660 Vivimed Labs Ltd.

Search Inside the pdf :

Vivimed Labs Ltd.

20 Nov 2015, 12:00AM

6.55

0.61%

Vivimed Labs Ltd: Entering a Period of Asset Rationalization (Nov 20, 2015)

Buy: Vivimed Labs Ltd.

Karvy

Strengthening balance sheet and trickle down to P&L: Vivimed Labs has morphed into a Pharma led company, built on its strong base in speciality chemicals. The company now operates across API, Research and Formulations assets acquired in last 4 years, which has tested the balance sheet. The company has sold 30% of its speciality chemicals (Spchem) segment for Rs.3800 Mn, which will be utilized to pare down the debt, addressing the main concern in last couple of years. In the next phase, we expect de-levered balance sheet and increasing bottom line contribution from pharmaceutical investments to strengthen its earnings base.

Vivimed Labs Ltd. is trading below all available SMAs

Is Vivimed Labs Ltd. worth buying?

182 Votes:

Buy 71.98%

Sell 18.68%

Hold 9.34%